๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
MBX Biosciences, Inc. (MBX)
NASDAQ: MBX ยท Real-Time Price ยท USD
53.42
+0.32 (0.60%)
At close: Nov 18, 2026, 4:00 PM EST
53.83
+0.41 (0.77%)
After-hours: Nov 18, 2026, 6:46 PM EST
โ† View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 10, 2026

Summary

Canvuparatide has entered phase III, with urine calcium and response rate among key measures. MBX 4291โ€™s blinded early data showed 7% weight loss at eight weeks; C1 data were expected in Q4, with phase II planned for 2027.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

All right. Well, welcome everybody, and thanks for joining us here at Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the Senior Biopharma Analysts here at Guggenheim, and I'm really pleased to be joined again this year by MBX Biosciences. To my immediate left is CEO Steve Hoerter. To his left is Sam Azoulay, Chief Medical Officer, and to Sam's left is John Smither, CFO. Maybe just to level set the playing field, thanks for joining us, of course, but Steve, you stepped into this CEO role in July after serving as Executive Chairman. Maybe just talk about where MBX is today, your top priorities for the company, and the next phase as both a late-stage rare endocrine drug company, but also a company with potential best-in-class long-acting obesity assets in the portfolio.

Steve Hoerter
CEO, MBX Biosciences

Yeah. Thanks, Seamus, and thanks for the invitation to join the conference this year. It's always a great conference, and Sam and John and I and the rest of the team are really delighted to be here. It's been a transformational year for MBX. If you think back to the summertime, we had the one-year, the 12-month open-label extension data for canvuparatide from the phase II AVAIL study demonstrating sustained clinical benefit for Canvu in patients with chronic hypoparathyroidism. Now, as we are in Q4, we started the phase III study of canvuparatide in chronic HP. We're really excited about physician receptivity to that study and patient enthusiasm, and we're on our way to the potential to become a commercial-stage company. So we're really excited on the Canvu front of where we are with this potential best-in-class therapy for patients.

Earlier in the summer, back in May, as you'll remember, we reported early blinded data from the phase I study of MBX 4291, and this is our long-acting co-agonist, GLP-1/GIP co-agonist for the treatment of obesity. Again, leveraging the platform technology that we've built that's part of MBX, the same prodrug technology that we use in canvuparatide, for example. In those early data, we were really excited about what we saw, even though blinded data, relatively small n.

So now, as we fast-forward, we'll talk about the balance of the year here in a second, but we're excited about the progress we're making with 4291 and the potential for that to really be fundamentally game-changing in the field of obesity. I think in terms of the priorities that we have for this year, it's really about continuing to execute on enrollment in the phase III canvuparatide study in HP while we also advance the rest of the obesity portfolio, including 4291.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. At your Obesity Day, you shared this initial blinded phase I data for 4291. Maybe just the key takeaways that you would encourage folks to really key into that informed views on weight loss and tolerability and what you really kind of see as the target product profile for that asset.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

Yeah. Thank you, Seamus. Let's start with just a reminder about the dose, that was the dose titration, right? It was an eight-week period during which patients were exposed to 30 mg weekly for four weeks, followed by 120 mg. I'm going to start with the PK, which is probably the most important learning because it's directly related to the platform, the PEP platform. If you look at the curve, the concentration of the active MBX 4291, you have a slow raise, smooth raise to the Cmax, right? We know that this raise, most of the case, with other product create a burst, and the burst is related to the GI intolerability. Here, it's a smooth. Then the concentration is sustained, and with the time to halve the Cmax of 26 days as compared to MOUNJARO, which was 21 days.

Here, you have a really already a confirmation for the monthly administration, right? Now looking at the weight loss, it was blinded, still blinded, and we had 7% weight loss at eight weeks. Again, with a range from 0% to 16%. If you look at the tolerability, again, excellent tolerability profile with this limited number of subject, but nevertheless, we had only one episode of diarrhea. Back to the PK curve, how to explain this good tolerability also is the way, the raise to the Cmax, right? The sustainability with the lack of fluctuation, and that explain why we got this tolerability. Good learning from this initial dose regimen.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Perfect. Steve, maybe you can talk about the upcoming data, and what you see as kind of the target product profile. Maybe following on to that, Sam, do you believe cohort one is sufficient to kind of predict an ability to move forward with confidence into phase II?

Steve Hoerter
CEO, MBX Biosciences

Yeah, so the milestone coming up for 4291 is, you're exactly right, is the unblinding of the study, and specifically with a focus on cohort C1. Sam just described the dose and schedule from B1 that we had as blinded data at the Obesity Day event back in May. The dose and schedule for this cohort C1 is 30 milligrams once weekly times four, followed by a monthly dose of 120 mg, followed by another monthly dose of 180 mg. The TPP that we're trying to achieve is competitive weight lowering, and when you look into the landscape at whether it's tirzepatide or sema or BARO from Pfizer, what you see is a 6%-8% weight loss at that 12-week time point. So we aim to be competitive with that.

The second part of the TPP is around having a true once monthly, and we think this is now fundamentally differentiating, even based on the data we showed, the PK data we showed back in May. There just are no other coagonists or monoagonists that offer true once-monthly dosing. So that's the second pillar of the TPP. Then the third, as Sam described, based on the PK profile and this slow rise to Cmax, is to differentiate based on tolerability. We can talk about relevant measures of that, Seamus. Vomiting is probably the easiest one. So GI intolerance generally, but vomiting specifically. When you look at tirzepatide data, phase III data, what you see, depending on dose and depending on study, is a range of anywhere from 8% rate of vomiting with low-dose tirzepatide up to 18% rate of vomiting.

So we think we have the potential to improve upon that based on the differentiated PK profile.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Sam, just following on to what this is going to help predict, is do you need C1 to be able to advance as well, or is B1, from your perspective, enough to really predict an ability to move forward into phase II?

Sam Azoulay
Chief Medical Officer, MBX Biosciences

I mean, C1 is a continuum of B1, right?

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

It's a longer period with an additional monthly dose of 180 mg, larger population exposed to the drug, so learning will be coming from C1. When you want to move a program forward, you look at the totality of evidence.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

Everything which you have generated in this phase I/IIa study, that will help us moving the program forward.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Okay, got it. I think if we were to say the competitive weight loss profile at 12 weeks, obviously, is a key point, but you've stated kind of 6%-8% is the competitive range. Rather than kind of get confused, I think we've already seen in the blinded weight loss data 7% at eight weeks. I don't want to confuse people and think that that's kind of a reversion with the next dose. How should we think about the data itself and your kind of positioning of that 6%-8% as part of the discussion?

Steve Hoerter
CEO, MBX Biosciences

Yeah, it's a good question, Seamus. You're right. When we had the disclosure of blinded data, we showed 7%. That was an N of eight, six on active, two on placebo. Very encouraging weight lowering, especially at the eight-week time point. What we don't yet know, but I think the further data that once we unblind and disclose may help us to better understand, is whether the unique PK profile of MBX 4291 translates into a differentiated PD profile. As you know, we get an infusion-like exposure with 4291 over the month period. When you look at the PK for the weeklies, it's as you'd expect. It's intermittent peaks and troughs over a weekly basis. We get very good coverage, very good exposure with 4291. There at least is the potential for that to translate into differentiated efficacy in weight lowering.

Nonetheless, what's still relevant is the competitive set, and the competitive set data is very clear at 6%-8% when you look across sema, tirzepatide, MET-097i. We think delivering on that would be an important component of our TPP, despite the fact that we might have the potential to do better than what's seen in the competitive set. Clearly, the benchmark is the competitive set weight lowering.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Right. What you're communicating is, don't get over your skis. These data could be potentially better than expected, but the best point to focus on is, even if it were better than expected, phase IIIs kind of can dial back at the same time, phase IIs can dial back. This is still early exploration.

Steve Hoerter
CEO, MBX Biosciences

It's certainly still early, and I think the competitive set weight lowering is the relative and important relevant, I should say, relevant benchmark for what we need to deliver.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

Steve Hoerter
CEO, MBX Biosciences

As we've talked about, it's an N of eight from May, which was early. We'll have a total of 30 subjects from cohort C1, 20 on active, 10 on placebo. Still relatively small numbers, but we believe it will be adequate for us to really understand the profile of MBX 4291 and the potential for us to achieve that TPP that we just talked about.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Perfect. In terms of what will be revealed in the fourth quarter, will that include B1 only, or should we expect it to include C1?

Steve Hoerter
CEO, MBX Biosciences

The disclosure is absolutely the C1 cohort from part C of the study. We haven't talked yet about exactly the contours of the disclosure, but our goal here is to have adequate data and to share an adequate level of information with key stakeholders, with investors, so that we understand the profile of MBX 4291. I think Sam's going to be in a position at that time to also talk about how we're thinking about the next step in the development process for MBX 4291. The team is very actively working, planning for success on getting ready to launch a phase II study next year. But we'll have more that we can share about that and our thinking when we get to the data disclosure.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Any additional learnings from the C2 cohort in particular, other than replication?

Steve Hoerter
CEO, MBX Biosciences

Yeah. We disclosed that C2 existed, if you will, back in May. That was when we talked about both C1 and C2. These are cohorts that have not been enrolling exactly concurrently. Nonetheless, I think the totality of the data from the study will be important for us as we think about the profile and as we think about the dose and schedule or doses and schedules that we might take into a phase II.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Strategic path for the obesity franchise, whether go it alone, partnership, how are you thinking about just the most reasonable time to consider either whether it's potential partners or the aggressiveness to move forward?

Steve Hoerter
CEO, MBX Biosciences

Yeah. This, as you know, is now the world's largest pharmaceutical market.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

Steve Hoerter
CEO, MBX Biosciences

We believe that we'll need to access someone else's balance sheet capabilities, if you will, to recognize full value for a drug like MBX 4291. We think getting to achieving clear evidence of differentiation is the important next step, whether that's from this phase I/II study or a larger phase II study. That will be, I think, necessary for us then to unlock potential for a future partnership to then fully maximize value.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Steve, one of the things that I think is interesting is you've already got a preclinical profile for a retatrutide-like molecule utilizing the PEP platform and the prodrug. It's hard to sort of automatically say that something like that translates, but what did we learn from, or there's abstract data so far, not the full poster, so I don't want to skate to the puck a little too soon. But how does that sort of translate for the platform, what you've seen so far preclinically, and your enthusiasm for the platform going forward?

Steve Hoerter
CEO, MBX Biosciences

Well, we now have very clear and convincing evidence that the platform can be leveraged to design peptides with a unique PK profile. So the prodrug technology is now validated clinically with Canvu. We have the early blinded data from 4291, which adds further validation. We'll get to our unblind here in the quarter to add yet more data. So now, the task ahead for us is, not to say that it's easy, but it's straightforward. Our goal is to apply the platform to other validated targets in obesity, where we can create value and meet unmet needs. So the triple G is a great example of that. As you alluded to when we disclosed our Q3 financial results yesterday, we also announced that we'll have preclinical data from 6180 at ObesityWeek here coming up shortly.

We've applied the same prodrug technology with the goal of getting to a once-monthly triple G, also avoiding the burst effect. So all of the hallmarks of our platform, we'll do that with a triple G. We have the potential to do that with our multi-agonist, where we look at a triple G construct together with a DACRA and other validated targets in obesity, and with the goal then of building out a robust obesity portfolio that is fundamentally differentiated.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Sam, when you look at just sort of the data so far, how reliable and repeatable do you think the PEP platform is at this point?

Sam Azoulay
Chief Medical Officer, MBX Biosciences

Well, when we look back at canvuparatide, we had already demonstrated in phase II, now we are in phase III. We have good argument that canvuparatide was behaving like a PTH replacement therapy, so we can say that the platform was translated into a good product from an efficacy and safety standpoint. When we look at MBX 4291, when we saw with the B1 cohort, it is already a good sign that we have something that would work beyond even these two assets.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

The triple G, what we used to call amycretin, or the DACRA triple G, is also a good example where we can go.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Let us talk about canvuparatide. Once-weekly PTH replacement therapy for chronic hypoparathyroidism. The unmet need, as you see it, what is kind of the unlock opportunity with a weekly replacement therapy, and what do you think the addressable market is?

Steve Hoerter
CEO, MBX Biosciences

This is a market where there remains clear unmet need. We have a competitor that was approved by the FDA in December of 2024. It has reported now six quarters of launch and is already on a $1.2 billion run rate in terms of revenue, which clearly validates the size of the opportunity in the U.S. for chronic HP. For us, we anchor to the extensive market research that we have done with both patients and physicians who tell us that the idea of having a once-weekly injectable instead of a once-daily injectable is incredibly attractive. Patients tell us that they would prefer a weekly over that daily, and we have the potential, we think, to compete not only for newly diagnosed patients upon a future approval, but also to switch patients from a daily injectable over to a once weekly.

It is a fairly straightforward commercial story. As Sam commented earlier, the data from AVAIL is clear. The open-label extension data at one year shows sustained benefit. This is now just about the confirmatory execution of the phase III study to deliver Canvu to patients who seem to prefer that profile. We are really excited about this, and we think it is ideally suited to a company of our size in terms of being able to commercialize this on our own, most certainly in the U.S. and potentially even outside of the U.S.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah. In terms of just what questions do you feel need to be answered in the phase III in particular, whether it be relative to AVAIL or relative to the competitor, and honestly, what do you think is the gap between sort of investor valuing this opportunity appropriately? We kind of feel like there is almost an order of magnitude difference between how we are thinking about it and maybe how you are thinking about it and where investors are.

Steve Hoerter
CEO, MBX Biosciences

Yeah, so maybe Sam, you want to take the first part of that.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Sure.

Steve Hoerter
CEO, MBX Biosciences

Then I will take the second.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

Yeah, the phase III is, in my view, it is a confirmatory trial.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

We want to see what we observed with the phase II AVAIL study, and it was longer exposure, six months exposure, placebo control, et cetera. But really, we are going to look at the response rate, the classical response rate, but there is another key secondary endpoint that would be a key factor for differentiation, which would be urine calcium.

Urine calcium is key in this disease because that is creating CKD. That is the cause of CKD, and through the stone, et cetera, stone formation. So, if you reduce urine, improve urine calcium excretion, you reduce the long-term chronic kidney disease. So that will be a key factor of differentiation in our phase III. We are confident from what we saw in phase II that we can get there.

Steve Hoerter
CEO, MBX Biosciences

Then in terms of how the street might view the opportunity, this is for us very, very clear in terms of the magnitude of the opportunity. I referenced earlier the competitor daily injectable and how that launch has gone, which has been super well, validates the market opportunity for us. We view canvuparatide as having best-in-class potential based on its profile, based on the market research that we have done. So I do think it seems to be underappreciated by investors that the value that can be created with canvuparatide on its own.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah. I am going to ask John a question. What is it, and it might be a little bit unfair, but what brought Michael Jordan out of retirement back to join MBX?

John Smither
CFO, MBX Biosciences

Well, first of all, I was invited via the Frazier folks, but it became evident quite quickly that this was a great opportunity in terms of the drugs that we were working on, the pipeline, the quality of the people, and it got sweetened even more once Steve came on board and I had a chance to work with Sam. It was a no-brainer. They were well-capitalized, great programs, the data was strong, bright future, the ability to commercialize a product. It had all the ingredients I look for in any of the situations I went into, and it was a bit of a no-brainer for me.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah. Just in terms of capitalizing the opportunity and the capital needs, where do we stand in terms of where the programs sit today, but also that ability to accelerate into phase IIs, larger obesity phase II programs? You can get a lot of answers relatively quickly in obesity programs. Just wondering how we sit today on the cash runway.

John Smither
CFO, MBX Biosciences

Cash runway, our guidance is the same and has been consistent over the last few quarters, and that is into 2029.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

John Smither
CFO, MBX Biosciences

You may have noticed in our earnings, we put another roughly $100 million on the balance sheet, which not only strengthens the balance sheet, but helps us continue to identify programs to put in the clinic, which we've disclosed. It also positions us well to complete our phase II around obesity, and clearly to also complete our phase III and still be in a good spot from a balance sheet standpoint. It all made complete sense. As Steve pointed out, with respect to how we think about obesity strategically, the thought of going into phase III with obesity, that's a pretty big lift from a capital raising standpoint. As we have discussed and continue to discuss, what's the best outcome for investors in terms of unlocking value and providing that value to them?

We think probably considering some type of strategic arrangement with somebody that's got the ability to really unlock that value in obesity makes sense. In the meantime, our capital needs for launching around canvuparatide are quite manageable, and we have the ability to do that.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Sam, I think there's one aspect, one point of interest that we're following very closely, which is this opportunity to use the PEP platform to improve upon something like a triple G. So what we see in the data for retatrutide is an ability to see extraordinary weight loss. But there are a lot of outstanding questions on tolerability. So what are you most excited about, and what do you see as kind of the flexibility that the PEP platform brings to tolerability improvement? Could be as a weekly or a monthly.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

I think you said it, Seamus. We see the platform as the ability to address this unresolved question today.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

Unsolved questions such as tolerability, but also the potential for monthly. If you can get the same weight loss that retatrutide showed, with a good tolerability profile and a monthly administration, I think there's a large segment of population who would need a lot of weight loss that could benefit from this treatment. The PEP platform is the key.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Yeah. Steve, from your perspective, it feels like with this kind of increased execution mode that you're moving into, is the solution now just kind of replication and validation of the platform that we have an opportunity to see repeatedly over the next, let's call it 12 - 24 months?

Steve Hoerter
CEO, MBX Biosciences

We're excited, Seamus, about the many ways that we have to win, whether it's with the Canvu phase III results and validating phase II, importantly, applying the platform technology, as Sam was just talking about, to high-value obesity targets. We're excited about sort of the rinse-and-repeat opportunity, leveraging the platform to deliver differentiated products and create a lot of value for shareholders.

Seamus Fernandez
Senior Biopharma Analyst, Guggenheim

Great. Well, it's f antastic having you here again this year. Looking forward to the upcoming, I guess, data reveal sometime soon.

Steve Hoerter
CEO, MBX Biosciences

Thanks, Seamus.

Sam Azoulay
Chief Medical Officer, MBX Biosciences

Thank you.

John Smither
CFO, MBX Biosciences

Thanks.